Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects
- PMID: 9145856
- PMCID: PMC163837
- DOI: 10.1128/AAC.41.5.982
Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects
Abstract
Aminosidine is an older, broad-spectrum aminoglycoside antibiotic that has been shown to be effective in in vitro and animal models against multiple-drug-resistant tuberculosis and the Mycobacterium avium complex. The objective of this randomized, parallel trial was to characterize the single-dose pharmacokinetics of aminosidine sulfate in healthy subjects (eight males, eight females). Sixteen adults (mean [+/- standard deviation] age, 27.6 +/- 5.6 years) were randomly allocated to receive a single, intramuscular aminosidine sulfate injection at a dose of 12 or 15 mg/kg of body weight. Serial plasma and urine samples were collected over a 24-h period and used to determine aminosidine concentrations by high-performance liquid chromatographic assay. A one-compartment model with first-order input, first-order output, and a lag time (Tlag) and with a weighting factor of 1/y2 best described the data. Compartmental and noncompartmental pharmacokinetic parameters were estimated with the microcomputer program WinNonlin. One subject was not included (15-mg/kg group) because of the lack of sampling time data. On average, subjects attained peak concentrations of 22.4 +/- 3.2 microg/ml at 1.34 +/- 0.45 h. All subjects had plasma aminosidine concentrations below 2 microg/ml at 12 h, and all but two subjects (one in each dosing group) had undetectable plasma aminosidine concentrations at 24 h. The dose-adjusted area under the concentration-time curve from 0 h to infinity of aminosidine was identical for the 12- and 15-mg/kg groups (9.29 +/- 1.5 versus 9.29 +/- 2.2 microg x h/ml per mg/kg; P = 0.998). Similarly, no significant differences (P > 0.05) were observed between dosing groups for peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life. A significant difference was observed for the volume of distribution (0.35 versus 0.41 liters/kg; P = 0.037) between the 12 and 15 mg/kg dosing groups. Now that comparable pharmacokinetic profiles between dosing groups have been demonstrated, therapeutic equivalency testing via in vitro pharmacokinetic and pharmacodynamic modelling and randomized clinical trials in humans should be conducted.
Similar articles
-
Pharmacokinetics and tolerability of aminosidine after repeated administrations using an optimal dose regimen in healthy dogs and in dogs with leishmaniosis.Vet Parasitol. 2014 Sep 15;205(1-2):365-70. doi: 10.1016/j.vetpar.2014.06.019. Epub 2014 Jun 20. Vet Parasitol. 2014. PMID: 24998095
-
Pharmacokinetics and dosing regimen of aminosidine in the dog.Vet Res Commun. 1996;20(6):533-41. doi: 10.1007/BF00396296. Vet Res Commun. 1996. PMID: 8950834 Clinical Trial.
-
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.Int J Clin Pharmacol Ther. 2002 May;40(5):198-206. doi: 10.5414/cpp40198. Int J Clin Pharmacol Ther. 2002. PMID: 12051571 Clinical Trial.
-
Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.Antimicrob Agents Chemother. 1994 Apr;38(4):799-804. doi: 10.1128/AAC.38.4.799. Antimicrob Agents Chemother. 1994. PMID: 8031049 Free PMC article. Clinical Trial.
-
Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Antimicrob Agents Chemother. 1998 Apr;42(4):885-8. doi: 10.1128/AAC.42.4.885. Antimicrob Agents Chemother. 1998. PMID: 9559801 Free PMC article. Clinical Trial.
Cited by
-
Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.Clin Pharmacokinet. 2020 Jul;59(7):827-847. doi: 10.1007/s40262-020-00871-5. Clin Pharmacokinet. 2020. PMID: 32100246 Free PMC article. Review.
-
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0. Clin Pharmacokinet. 2018. PMID: 28756612 Free PMC article. Review.
-
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.Antimicrob Agents Chemother. 2013 Oct;57(10):4809-15. doi: 10.1128/AAC.00628-13. Epub 2013 Jul 22. Antimicrob Agents Chemother. 2013. PMID: 23877689 Free PMC article. Clinical Trial.
-
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Ther Clin Risk Manag. 2012;8:323-8. doi: 10.2147/TCRM.S30139. Epub 2012 Jun 22. Ther Clin Risk Manag. 2012. PMID: 22802694 Free PMC article.
-
Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Open Med Chem J. 2011;5:31-9. doi: 10.2174/1874104501105010031. Epub 2011 Mar 9. Open Med Chem J. 2011. PMID: 21629509 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources